Text Size

Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by Hillel Yaffe Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT01078792
First received: March 1, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted
  Purpose

To determine the possible association of prothrombin fragments 1+2 elevation with incidents of pulmonary embolism in patients with COPD exacerbation.


Condition Intervention
Pulmonary Disease, Chronic Obstructive
Disease Exacerbation
Pulmonary Embolism
Prothrombin Fragments
 Other: CT pulmonary angio, blood tests

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hillel Yaffe Medical Center:

Groups/Cohorts Assigned Interventions
COPD exacerbation
Patients admitted to hospital with COPD exacerbation
 Other: CT pulmonary angio, blood tests

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients admitted to hospital due to COPD exacerbation

Criteria

Inclusion Criteria:

  • COPD exacerbation
  • Able to give informed consent
  • Able to perform spirometry

Exclusion Criteria:

  • Known malignancy
  • Known hypercoagulable state
  • Receiving anticoagulant treatment
  • Pregnancy
  • Renal failure
  • Allergy to Iodine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01078792

Locations
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: M Beckerman, MD         marinellab@hy.health.gov.il    
Principal Investigator: M Beckerman, MD            
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

No publications provided

Responsible Party: Marinella Beckerman, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01078792     History of Changes
Other Study ID Numbers: 0001-10
Study First Received: March 1, 2010
Last Updated: March 1, 2010
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Chronic Disease
Embolism
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Pulmonary Embolism
Disease Progression
 Disease Attributes
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive

ClinicalTrials.gov processed this record on May 23, 2013